Identification of tissue for debridement
View Patent ↗Provided are methods of determining whether a cell in a tissue site is viable or nonviable. Also provided are methods of debriding tissue from a tissue site. Further provided are kits comprising a compound that distinguishes between viable and nonviable cells and instructions for using the compound on a tissue site. Additionally, the use of a compound that distinguishes between viable and nonviable cells is provided, where the use is to determine whether a cell in a tissue site is viable or nonviable. Also provided is a use of a compound that distinguishes between viable and nonviable cells, where the use is for the manufacture of the above-described kit.
1. A method of determining the viability of a cell in a wound tissue site comprising:
adding a compound to the wound tissue site that identifies a protein having an elevated level or a depleted level during cell death as compared to a normal level in healthy tissue, wherein the protein is cytochrome c, glyceraldehyde 3-phosphate dehydrogenase, vimentin, lamin A, soluble galactose-binding lectin 7, collagen, fibronectin 1, serine protease inhibitor 2b, transferrin, or hemoglobin;
allowing the compound to react with the protein; and
determining whether the protein has either an elevated level or a depleted level as an indication that the cell is nonviable.
2. The method of claim 1 , wherein the compound identifies a protein having an elevated level during cell death.
3. The method of claim 2 , wherein the protein is cytochrome c, galactosidase, HMGB1, glyceraldehyde 3-phosphate dehydrogenase, vimentin, lamin A, soluble galactose-binding lectin 7, or collagen.
4. The method of claim 2 , further comprising:
placing a solid sheet comprising the compound on the wound tissue site, wherein the compound is capable of binding or reacting to the released protein on the tissue site, then
determining whether the protein is bound or has reacted to the compound,
wherein areas of the sheet comprising protein bound to the compound is nonviable tissue.
5. The method of claim 4 , wherein the sheet is a starch film, a poly(D,L-lactide-co-glycolide), a polyglycolic acid, a poly-(L-lactic acid), or a polyhydroxyalkanoate.
6. The method of claim 1 , wherein the compound identifies a protein that is depleted during cell death.
7. The method of claim 6 , wherein the protein is fibronectin 1, serine protease inhibitor 2b, transferrin, or hemoglobin.
8. The method of claim 1 , wherein the compound comprises a dye.
9. The method of claim 8 , wherein the dye is fluorescein diacetate, JC-1, propidium iodide, dihydrorhodamine 123 or trypan blue.
10. The method of claim 1 , wherein the compound comprises an antibody binding site.
11. The method of claim 1 , wherein the compound comprises an aptamer.
12. The method of claim 1 , wherein the compound comprises a detectable marker.
13. The method of claim 1 , wherein the compound comprises an antibody or aptamer conjugated to a detectable marker.
14. The method of claim 1 , further comprising selectively debriding identified nonviable tissue.
15. A method of determining the viability of a cell in a dermal tissue engineering construct comprising cells, the method comprising:
adding a compound to the dermal tissue that identifies a protein having an elevated level or a depleted level during cell death as compared to a normal level in healthy tissue, wherein the protein is cytochrome c, glyceraldehyde 3-phosphate dehydrogenase, vimentin, lamin A, soluble galactose-binding lectin 7, collagen, fibronectin 1, serine protease inhibitor 2b, transferrin, or hemoglobin;
allowing the compound to react with the protein; and
determining whether the protein has either an elevated level or a depleted level as an indication that the cell is nonviable.